Physician
Jhansi R Ganesan, MD PC
Jhansi R Ganesan, MD PC was paid $3.68M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoJHANSI R GANESAN, MD PC
LAUREL, MD 20707
LAUREL, MD 20707
33aNPI1386191419assigned 09/07/2016
33bProvider typeFamily Medicine Physician
28Total paid$3.68M
24GClaims94,718
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Maryland
Rank by total paid#8 of 287
Median peer was paid$78K
This provider vs. median47×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 435 | $10K | |
| 2019 | 347 | $8K | |
| 2020 | 17,776 | $583K | |
| 2021 | 17,438 | $657K | |
| 2022 | 20,945 | $845K | |
| 2023 | 20,079 | $834K | |
| 2024incomplete | 17,698 | $740K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 14,040 | 12,851 | $1.23M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 5,340 | 5,096 | $692K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 8.6% | 2,910 | 2,851 | $318K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 8.3% | 2,563 | 2,514 | $306K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.1% | 2,748 | 2,666 | $299K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.9% | 1,787 | 1,655 | $179K |
| 92552 | 4.0% | 5,914 | 5,782 | $148K | |
| 90686 | 2.3% | 3,692 | 3,516 | $84K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.4% | 5,068 | 4,933 | $52K |
| 96127 | 1.2% | 7,137 | 6,971 | $44K | |
| D1206 | Topical application of fluoride varnish | 1.0% | 1,523 | 1,505 | $38K |
| 87428 | <1% | 731 | 716 | $25K |
53 more codes
| 90698 | <1% | 1,052 | $24K | |
| 99177 | <1% | 4,706 | $24K | |
| 90670 | <1% | 1,024 | $23K | |
| 94760 | <1% | 13,041 | $18K | |
| 87430 | <1% | 1,246 | $16K | |
| 92587 | <1% | 876 | $15K | |
| 99173 | <1% | 5,861 | $15K | |
| 90651 | <1% | 354 | $9K | |
| 96160 | <1% | 3,496 | $8K | |
| 90680 | <1% | 308 | $7K | |
| 94375 | <1% | 216 | $7K | |
| 90656 | <1% | 288 | $7K | |
| 90633 | <1% | 278 | $6K | |
| 90716 | <1% | 266 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 564 | $5K |
| W7000 | <1% | 1,013 | $5K | |
| 90707 | <1% | 215 | $5K | |
| 90734 | <1% | 194 | $5K | |
| 90621 | <1% | 184 | $4K | |
| 88738 | <1% | 1,018 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 98 | $4K |
| 0072A | <1% | 107 | $4K | |
| 0071A | <1% | 101 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 75 | $3K |
| 96161 | <1% | 1,307 | $3K | |
| 90619 | <1% | 124 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 267 | $3K |
| 2015F | <1% | 278 | $3K | |
| 87400 | <1% | 430 | $3K | |
| 90744 | <1% | 119 | $3K | |
| 90661 | <1% | 131 | $3K | |
| 83655 | <1% | 203 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 147 | $2K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 14 | $2K |
| 87420 | <1% | 146 | $2K | |
| 87807 | <1% | 92 | $967.00 | |
| 90677 | <1% | 36 | $915.28 | |
| 90715 | <1% | 28 | $651.84 | |
| 94664 | <1% | 58 | $511.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 52 | $410.00 |
| 83718 | <1% | 54 | $380.52 | |
| 90696 | <1% | 12 | $279.36 | |
| 90620 | <1% | 12 | $279.36 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 149 | $248.32 |
| 82465 | <1% | 54 | $180.52 | |
| 36416 | <1% | 467 | $180.00 | |
| 81002 | <1% | 65 | $171.80 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 91 | $155.37 |
| 85018 | <1% | 68 | $152.37 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 105 | $12.65 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 30 | $1.20 |
| 91307 | <1% | 76 | $0.07 | |
| 99072 | 0% | 69 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGANESAN, JHANSI (PRESIDENT)